OBJECTIVES: Clinical and health-economic criteria to accurately assess the value of new immuno-oncology (IO) drugs are currently undetermined. The aim of this study was to assess the current knowledge about these criteria among the Spanish scientific community. METHODS: The Delphi method was used to survey a multi-disciplinary group of Spanish oncologists [melanoma, lung, or genitourinary-specialists (hospital/regional managers)], hospital pharmacists (Genesis and/or GEDEFO) and health-economists (universities/public entities). The questionnaire consisted of 36 items with a Likert rating scale of 9 points (9 = full agreement). Consensus was considered when more than two-thirds of the responses were in the same tercile. RESULTS: A total of 101 experts where invited (40.6% oncologists; 44.6% hospital pharmacists and 14.8% health-economists). 81% and 67% questionnaires were retrieved in the first and second round, respectively. Only two rounds were required as variability was less than 10% (delta CV 7.1%). Internal consistency of the questionnaire was high (α C: 0.886), as was the correlation between the rounds (R of Spearman: 0.946) Consensus was attained in 29 items. Most experts agreed on: i) the need to improve scales and quality of life-related measurements (96%, CI95%=90.7-98.8%); ii) the need for Health Authorities to define a cost-effectiveness threshold (91%, CI95%=84.5-97.9%) and if a different one for “end of life treatments” is required (81%, CI95%=71.7-90.3%); iii) the importance of considering cost-effectiveness data along with the budget impact of oncologic therapies (97%, CI95%=93.1-99,0%); iv) the need to consider the societal perspective in the assessment of advanced cancer treatments (94%, CI95%=88.5-99.7%). Lack of consensus was observed regarding the use of mean or median overall survival as best efficacy variable for IO therapies CONCLUSIONS: Consensus in both clinical and pharmaco-economic aspects was high among the different health professionals. Lack of agreement in specific questions suggests the need for further research on these new therapeutic options.